CA2513102C - Substituted pyrazoles, compositions containing such compounds and methods of use - Google Patents

Substituted pyrazoles, compositions containing such compounds and methods of use Download PDF

Info

Publication number
CA2513102C
CA2513102C CA2513102A CA2513102A CA2513102C CA 2513102 C CA2513102 C CA 2513102C CA 2513102 A CA2513102 A CA 2513102A CA 2513102 A CA2513102 A CA 2513102A CA 2513102 C CA2513102 C CA 2513102C
Authority
CA
Canada
Prior art keywords
groups
optionally substituted
group
halo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2513102A
Other languages
English (en)
French (fr)
Other versions
CA2513102A1 (en
Inventor
Emma Parmee
Subharekha Raghavan
Teresa Beeson
Dong-Ming Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2513102(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2513102A1 publication Critical patent/CA2513102A1/en
Application granted granted Critical
Publication of CA2513102C publication Critical patent/CA2513102C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2513102A 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use Expired - Fee Related CA2513102C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44282803P 2003-01-27 2003-01-27
US60/442,828 2003-01-27
PCT/US2004/001927 WO2004069158A2 (en) 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
CA2513102A1 CA2513102A1 (en) 2004-08-19
CA2513102C true CA2513102C (en) 2011-03-22

Family

ID=32850762

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2513102A Expired - Fee Related CA2513102C (en) 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use

Country Status (8)

Country Link
US (2) US7572922B2 (https=)
EP (1) EP1590336B1 (https=)
JP (2) JP4560035B2 (https=)
AT (1) ATE490244T1 (https=)
AU (2) AU2004210127B2 (https=)
CA (1) CA2513102C (https=)
DE (1) DE602004030318D1 (https=)
WO (1) WO2004069158A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
JP2006522130A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール
DE602005006806D1 (de) * 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
AU2005272043B2 (en) * 2004-07-07 2010-07-29 Merck Sharp & Dohme Corp. Pyrazole amide derivatives, compositions containing such compounds and methods of use
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8703805B2 (en) 2005-06-27 2014-04-22 Exelixis Patent Company Llc Modulators of LXR
JP2009502923A (ja) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2402320A1 (en) 2006-03-31 2012-01-04 Novartis AG Anorectic agents
WO2007136577A2 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20090094125A (ko) * 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
PT2178858E (pt) 2007-08-02 2012-02-24 Recordati Ireland Ltd Novos compostos heterocíclicos como antagonistas de mglu5
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
EP2210876B1 (en) * 2007-11-01 2015-05-20 Takeda Pharmaceutical Company Limited Heterocyclic compound as glucagon antagonist
CA2710696C (en) 2007-12-26 2016-05-17 Andrew J. Borleske Optimized data collection in a wireless fixed network metering system
GEP20135844B (en) * 2008-03-05 2013-06-10 Takeda Pharmaceutical Heterocyclic compound
EP2291358B1 (en) 2008-05-16 2018-03-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
AU2009272033B2 (en) 2008-07-17 2011-10-13 Asahi Kasei Pharma Corporation Nitrogenated heterocyclic compound
CA2770298C (en) 2008-08-13 2017-06-20 Metabasis Therapeutics, Inc. Glucagon antagonists
EP2346830B1 (en) * 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2350020B1 (en) * 2008-10-03 2014-08-13 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
EP2344467A1 (en) * 2008-10-10 2011-07-20 Lonza Ltd. Process for preparing 2-alkyl-3-aroyl-5-nitro-benzofurans
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
AR088020A1 (es) * 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
EP2637659B1 (en) 2010-11-09 2016-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
HRP20161177T1 (hr) 2011-02-08 2016-11-04 Pfizer Inc. Modulator glukagonskog receptora
AU2012288493B2 (en) 2011-07-22 2015-08-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
CN106117194A (zh) * 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
TW201811752A (zh) * 2016-09-06 2018-04-01 比利時商健生藥品公司 用作升糖素受體拮抗劑之吲唑衍生物
TWI757332B (zh) * 2016-09-06 2022-03-11 比利時商健生藥品公司 使用作為升糖素受體拮抗劑之吲唑衍生物
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
EP4452253A4 (en) 2021-12-23 2026-04-15 The Katholieke Univ Leuven 2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD
WO2025034531A1 (en) * 2023-08-04 2025-02-13 The University Of Vermont And State Agricultural College Small molecule allosteric modulator to pac1 receptor and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
BE1009189A3 (fr) * 1995-03-14 1996-12-03 Solvay Procede pour la fabrication d'un corps creux.
EP0859771A4 (en) 1995-10-31 2000-03-15 Merck & Co Inc SUBSTITUTED PYRIDYLPYRROLE, PREPARATIONS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE USE THEREOF
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP0959885A4 (en) 1996-11-20 2002-07-17 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE
WO1998021957A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
EP0945438B1 (en) * 1996-12-12 2003-03-05 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
EA199900837A1 (ru) 1997-04-18 2000-10-30 Дж.Д.Сирл Энд Ко. Способ применения ингибиторов циклооксигеназы-2 для предупреждения сердечно-сосудистых расстройств
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1024134A4 (en) * 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
ES2304797T3 (es) 1997-12-19 2008-10-16 Amgen Inc. Compuestos de piridina y piridazina sustituidos y su uso farmaceutico.
TR200100773T2 (tr) 1998-09-17 2001-07-23 Bristol-Myers Squibb Company Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi
WO2000069810A1 (en) 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
MXPA02001393A (es) * 1999-08-10 2002-08-12 Bayer Agrochem Kk Herbicidas derivados de tetrazolinona.
HK1045991B (en) * 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
PL359619A1 (en) 2000-06-23 2004-08-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
EP1463715A1 (en) 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
TWI262917B (en) * 2002-02-01 2006-10-01 Dainippon Sumitomo Pharma Co 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
EP1523350B1 (en) 2002-07-19 2011-04-13 Baxter International Inc. System for performing peritoneal dialysis
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
WO2004050039A2 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
DE10317108A1 (de) 2003-04-14 2004-11-11 Mutzbauer, Till S., Dr. Dr.med. Transdermal applizierbares Beruhigungs- und Sedierungsmittel
BRPI0409447A (pt) 2003-04-14 2006-04-18 Inst For Pharm Discovery Inc ácidos fenilalcanóicos substituìdos
AU2004238240A1 (en) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
US7625938B2 (en) * 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
US7572922B2 (en) 2009-08-11
US20060084681A1 (en) 2006-04-20
JP2006516622A (ja) 2006-07-06
EP1590336A2 (en) 2005-11-02
EP1590336A4 (en) 2008-12-17
JP4560035B2 (ja) 2010-10-13
JP2010150267A (ja) 2010-07-08
AU2004210127B2 (en) 2009-10-01
ATE490244T1 (de) 2010-12-15
US7989475B2 (en) 2011-08-02
CA2513102A1 (en) 2004-08-19
WO2004069158A3 (en) 2005-01-20
US20090215825A1 (en) 2009-08-27
JP5260569B2 (ja) 2013-08-14
AU2004210127A1 (en) 2004-08-19
WO2004069158A2 (en) 2004-08-19
EP1590336B1 (en) 2010-12-01
DE602004030318D1 (de) 2011-01-13
AU2009240856A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
CA2513102C (en) Substituted pyrazoles, compositions containing such compounds and methods of use
AU2005269792B9 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
AU2005272043B2 (en) Pyrazole amide derivatives, compositions containing such compounds and methods of use
AU2008229701B2 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
AU2006303986B2 (en) Acyl indoles, compositions containing such compounds and methods of use
JP2006528687A (ja) ベンズイミダゾール、こうした化合物を含有する組成物および使用方法
JP2002516909A (ja) 置換１−（４−アミノフェニル）ピラゾール及び抗炎症剤としてのそれらの使用
JP2000513386A (ja) Ｃｏｘ−２阻害物質としてのインドール化合物
HU211532A9 (en) Pyrazole derivatives, and pharmaceutical composition comprising the same
CA2508581A1 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
JP2003073360A (ja) オピオイド受容体リガンドとしての１−ジフェニルメチル−ピラゾール誘導体
NZ714027A (en) Heterocyclic derivates

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220124